Miercoles 7 NOV 2012 . AACR CONGRESS .
*.- In Vitro Study of Yondelis in Combination with a Panel of PARP Inhibitors .
V. Moneo1, G. Santamaria1, G. Tarazona1, P. Martinez1, B. de Castro1, S. Cascajares1, C. Cuevas1, L. Garcia-Fernandez1, C.M. Galmarini1 1PharmaMar S.A. Sociedad Unipersonal, Cell Biology, Colmenar Viejo (Madrid), Spain .
*.- TC-NER Dependent Degradation of RNA Pol II in Response to Lurbinectedin (PM01183) .
G. Santamaría1, J.F. Martínez-Leal1, C. Cuevas1, L. Garcia-Fernandez1, C.M. Galmarini1 1PharmaMar S.A. Sociedad Unipersonal, Cell Biology, Colmenar Viejo (Madrid), Spain .
*.- Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models .
R. Frapolli1, E. Bello1, M. Zangarini1, P. Zucchetti1, P. Aviles2, M. D'Incalci1 1Mario Negri Institute for Pharmacological Research, Laboratory of Cancer Pharmacology Oncology Department, Milano, Italy ; 2PharmaMar S.A.U., R&D, Colmenar Viejo (Madrid), Spain .
*.- Lurbinectedin (PM01183) in Combination with Gemcitabine in Patient-Derived, Pancreatic Ductal Adenocarcinoma (PDA) Xenografts .
P.P. López-Casas1, M. Hidalgo1, M.J. Guillén2, F. Sarno1, O. Cataluña2, M. Palomares2, C. Cuevas2, P. Aviles2 1Centro Nacional de Investigaciones Oncológicas, Hospital de Madrid, Madrid, Spain ; 2PharmaMar S.A.U., R&D, Colmenar Viejo (Madrid), Spain .
*.- Lurbinectedin (PM01183): Pharmacokinetics/Pharmacodynamic (PK/PD) Properties in Pancreas, Ovarian and NSCLC Xenografts .
P. Aviles1, M.V. Céspedes2, M.J. Guillén3, P. Alamo2, A. Bishop3, A. Gallardo2, T. Pernice3, R. Mangues2, C. Cuevas3 1PharmaMar S.A.U, R&D, Colmenar Viejo (Madrid), Spain ; 2Institut d`Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau and CIBER de Bioingenieria Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain ; 3PharmaMar S.A.U., R&D, Colmenar Viejo (Madrid), Spain
*.- Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts .
R. Mangues1, M.V. Céspedes1, M.J. Guillén2, P. Alamo1, R. López2, A. Gallardo1, P. Nuñez2, C. Cuevas2, P. Aviles2 1Institut d`Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau and CIBER de Bioingenieria Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain ; 2PharmaMar S.A.U., R&D, Colmenar Viejo (Madrid), Spain .
8 NOV :
*.- Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas .
Y. Pignochino1, F. Capozzi1, C. Dell'Aglio1, M. Basiricò1, L. D'ambrosio1, D. Galizia1, E. Palesandro1, M.S. Benassi2, M. Aglietta1, G. Grignani1 1Ircc Candiolo, Medical Oncology, Torino, Italy ; 2Istituti Ortopedici Rizzoli, Experimental Oncology, Bologna, Italy